The Board of Regents of The University of Texas System;argenx BVBA
发明人:
ULRICHTS, Peter,BLANCHETOT, Christophe,DREIER, Torsten,DE HAARD, Johannes,WARD OBER, E. Sally,ONGENAE, Nicolas G.H.
申请号：
LT14827372
公开号：
LT3087095T
申请日:
2014.12.23
申请国别(地区):
LT
年份:
2019
代理人:
摘要：
Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
